• NanoViricides secured DRC regulatory clearance to start a Phase II trial of its NV-387 oral gummies for Bundibugyo Ebola.
• The study was registered in the Pan African Clinical Trials Registry under ID PACTR202608748555077.
• First patient dosing is expected within one to two weeks, with drug supply already delivered to the Ituri site.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609080830ACCESSWRNAPR_____1217962) on September 08, 2026, and is solely responsible for the information contained therein.